Document is current
Any future updates will be listed below
-
Authors
Nakagawa, Tatsuya
Okumura, Naoki
Ikegawa, Masaya
Toyama, Yumiko
Nirasawa, Takashi
Mascarelli, Frederic
Vaitinadapoule, Hanielle
Aouimeur, Ines
He, Zhiguo
Gain, Philippe
Thuret, Gilles
Koizumi, Noriko
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (21K09731)
Japan Agency for Medical Research and Development (JP22ek0109590)
Japan Society for the Promotion of Science and by the Hubert-Curien Partnership (SAKURA 41024TE)
Japan Society for the Promotion of Science and by the Hubert-Curien Partnership (SAKURA 41024TE)
the Region Auvergne Rhône Alpes, Pack Ambitiuon internationale (2020-P010O003)
Ministère des Affaires Etrangères et du Développement International, Ministère de l’Education Nationale, de l’Enseignement Supérieur et de la Recherche
- License Information
-
More Information
Article History
Received: 25 December 2022
Accepted: 15 June 2023
First Online: 27 June 2023
Competing interests
: Naoki Okumura and Noriko Koizumi are co-founders of ActualEyes Inc., which is currently developing a pharmaceutical therapy for treating Fuchs endothelial corneal dystrophy. Gilles Thuret and Philippe Gain patented a retro-illumination process intended to be used for Fuchs endothelial corneal dystrophy. Other authors do not have a competing financial interest.
